• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Conferences

Conferences

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)

November 5, 2022 | American Society of Nephrology (ASN) Kidney Week
Rizk, et. al.

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)

Dana V Rizk, Vlado Perkovic, Richard Lafayette, Hernan Trimarchi, Jonathan Barratt, Kevin Caroll, Vladimir Tesar, Hong Zhang, Yusuke Suzuki, Adrian Liew, Muh Geot Wong, Bruce Leslie, Mohit Mathur, Jeffrey Hafkin

>SEE POSTER

Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy

November 3, 2022 | American Society of Nephrology (ASN) Kidney Week
Kooienga, et. al.

Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy

Laura Kooienga, Yusuke Suzuki, Bobby Chacko, Muh Geot Wong, Jonathan Barratt, Chris Oh, Manisha Sahay, Mohit Mathur, Xiaofeng Wang, Jill Yarbrough, Brian J G Pereira

>SEE POSTER

Role of APRIL in IgAN Pathophysiology

October 4, 2022 | Rare & Genetic Kidney Disease Drug Development Conference

Role of APRIL in IgAN Pathophysiology

Mohit Mathur

Role of Complement Cascade in Glomerular Diseases

October 4, 2022 | Rare & Genetic Kidney Disease Drug Development Conference

Role of Complement Cascade in Glomerular Diseases

Mohit Mathur

A potent anti-C5aR1 Antibody for Treatment of ANCA Associated Vasculitis

September 27, 2022 | Complement-based Drug Development Summit

A potent anti-C5aR1 Antibody for Treatment of ANCA Associated Vasculitis

Karthik Viswanathan

Brief Human IL-2 Mutein Therapy Induces Foxp3+ T-Regulatory Cell Expansion and Donor-Specific Allograft Tolerance

June 4, 2022 | American Transplant Congress
Liqing Wang et al.

Brief Human IL-2 Mutein Therapy Induces Foxp3+ T-Regulatory Cell Expansion and Donor-Specific Allograft Tolerance

Liqing Wang, Gregory J Babcock, Wayne W Hancock

A Novel IL-2 Mutein Selectively Expands Regulatory T Cells and Prolongs Skin Graft Survival

June 4, 2022 | American Transplant Congress
Orhan Efe et al.

A Novel IL-2 Mutein Selectively Expands Regulatory T Cells and Prolongs Skin Graft Survival

Orhan Efe, Thiago J Borges, Rodrigo B Gassen, Leela Morena, Ayman Al Jurdi, Isadora T Lape, Gregory J Babcock, Joren C Madsen, Leonardo V Riella

Selective Regulatory T Cell Expansion by Novel IL-2 Mutein Prolongs Skin Transplant Survival

June 4, 2021 | American Transplant Congress
Thiago J Borges et al.

Selective Regulatory T Cell Expansion by Novel IL-2 Mutein Prolongs Skin Transplant Survival

Thiago J Borges, Orhan Efe, Rodrigo B Gassen, Ayman Al Jurdi, Isadora T Lape, Gregory J Babcock, Scott M Carlson, Joren C Madsen, Leonardo V Riella

>SEE POSTER

Targeting C5aR1 for the Treatment of ANCA-associated Vasculitis

March 3, 2020 | Festival of Biologics

Targeting C5aR1 for the Treatment of ANCA-associated Vasculitis

Greg Babcock

Monovalent IgGs as a Tool for Characterizing Antibody Binding and Function

January 20, 2020 | Peptalk
Booth, et. al.

Monovalent IgGs as a Tool for Characterizing Antibody Binding and Function

Brian J Booth, Madison Belyea, Danielle Wisheart, Daisuke Oka, Brian Best, James C Delaney, Boopathy Ramakrishnan, Gregory J Babcock, Zachary Shriver, Karthik Viswanathan

>SEE POSTER
  • 1
  • 2
  • 3
  • Next Page »

© 2023 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design